

UNIVERSITY OF BIRMINGHAM

University of Birmingham
Research at Birmingham

Newborn Pulse Oximetry Screening: Which Algorithm is Best?

Ewer, Andrew; Martin, Gerard

DOI:

[10.1542/peds.2016-1206](https://doi.org/10.1542/peds.2016-1206)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Ewer, A & Martin, G 2016, 'Newborn Pulse Oximetry Screening: Which Algorithm is Best?', *Pediatrics*, vol. 138, no. 5. <https://doi.org/10.1542/peds.2016-1206>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked 12/07/2016

Newborn Pulse Oximetry Screening: Which Algorithm Is Best?

Andrew K. Ewer, Gerard R. Martin

Pediatrics Nov 2016, 138 (5) e20161206; DOI: 10.1542/peds.2016-1206

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

UNIVERSITY OF BIRMINGHAM

Research at Birmingham

Newborn Pulse Oximetry Screening: Which Algorithm is Best?

Ewer, Andrew; Martin, Gerard

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Ewer, A & Martin, G 2016, 'Newborn Pulse Oximetry Screening: Which Algorithm is Best?' *Pediatrics*.

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked 12/07/2016

General rights

When referring to this publication, please cite the published version. Copyright and associated moral rights for publications accessible in the public portal are retained by the authors and/or other copyright owners. It is a condition of accessing this publication that users abide by the legal requirements associated with these rights.

- You may freely distribute the URL that is used to identify this publication.
- Users may download and print one copy of the publication from the public portal for the purpose of private study or non-commercial research.
- If a Creative Commons licence is associated with this publication, please consult the terms and conditions cited therein.
- Unless otherwise stated, you may not further distribute the material nor use it for the purposes of commercial gain.

Take down policy

If you believe that this document infringes copyright please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

PEDIATRICS®

Newborn Pulse Oximetry Screening: Which Algorithm is Best?

Journal:	<i>Pediatrics</i>
Manuscript ID	2016-1206.R2
Article Type:	Pediatrics Perspectives
Date Submitted by the Author:	01-Jul-2016
Complete List of Authors:	Ewer, Andrew; University of Birmingham, Institute of Metabolism and Systems Research; Birmingham Women's NHS Foundation Trust, Neonatal Unit Martin, Gerard; Children's National Medical Center, Division of Cardiology
Keyword/Topic:	Neonatology < Fetus/Newborn Infant, Cardiology

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Newborn Pulse Oximetry Screening: Which Algorithm is Best?

Short title (running head): Algorithms for Newborn Pulse Oximetry Screening

Andrew K Ewer,^{1,2} Gerard R Martin³

Affiliations

- 1. Department of Neonatology
Birmingham Women’s Hospital NHS Trust
Birmingham
B15 2TG
UK
- 2. Institute of Metabolism and Systems Research
College of Medical and Dental Sciences
University of Birmingham
Birmingham
B15 2TT
UK
- 3. Children's National Health System
Washington DC
USA

Address for correspondence: Professor A K Ewer, Neonatal Unit, Birmingham Women’s Hospital, Edgbaston, Birmingham UK. B15 2TG. Email: a.k.ewer@bham.ac.uk

Funding source: No funding was secured for this study

Financial disclosure: The authors have no financial relationships relevant to this article to disclose.

Conflict of Interest: The authors have no conflicts of interest to disclose.

Abbreviations: POS – Pulse Oximetry screening, CCHD – Critical congenital heart defect

Contributor’s statements: Both authors discussed the contents initially, AKE wrote the first draft and edited the final draft. GRM provided further comments and edited the final draft. Both authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Pediatrics Perspectives

Word count: 1332

References: 9

Pulse oximetry screening (POS) is an accepted test that improves detection of critical congenital heart defects (CCHD).¹ Although outcome data are lacking, there is agreement among clinicians that POS identifies babies with CCHD before discharge. Following consideration by an expert workgroup, POS was adopted onto the US Recommended Uniform Screening Panel² and other countries have either introduced, or are considering introducing, POS.¹ Despite this, there is considerable variation in screening, particularly the algorithm used.³

Differences include: i) pre- and post-ductal saturations (right hand and either foot) versus single post-ductal measurement (foot only) and ii) timing of screening (i.e. before or after 24 hours). In algorithms using two limb measurements there are also differences - inclusion of saturations <95% in one or both limbs and the absolute value of the differential between the two in determining positive results.¹ So, which algorithm is best?

When evaluating algorithms, it is important to consider sensitivity, specificity, false positive (FP) and false negative rate. It is also vital that screening leads to timely diagnosis - before presentation with acute collapse. Meta-analysis of POS studies shows that overall, the test has modest sensitivity (~ 75%) and high specificity (99.8%), with no significant difference in sensitivity between pre/post vs. post-ductal testing or timing.³ However, analysis of raw saturation data from babies who had both limb measurements, shows that some babies with CCHD would be missed by post-ductal testing alone.¹ In addition, the FP rate is significantly higher with earlier testing (<24 hrs).³ These factors were deemed important by the USA workgroup considering the POS evidence and their recommendation was that screening should

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

include both pre/post measurements and be performed after 24 hours.² This resulted in the algorithm introduced in the USA (figure 1).²

A low FP rate is clearly important; but the strict definition of a FP is any test positive baby who does not have CCHD. Interestingly, analysis of recent POS studies shows that many FPs (30-80%) have alternative non-cardiac conditions (e.g. congenital pneumonia, early-onset sepsis or pulmonary hypertension), which may be as equally life-threatening as CCHD if diagnosed late.^{1,4-6} These conditions may benefit from earlier diagnosis and represent an important additional advantage. Also, important non-critical cardiac defects (e.g. AVSD, VSD) are identified as FPs.^{1,4-6}

Timing of the test

In published studies that adopted earlier screening,^{3,6} the FP rate was higher, but more non-cardiac disease was identified; this is because such babies are more likely to develop hypoxemia within 24 hours and therefore be picked up by earlier screening. Careful analysis of later screening studies^{4,5} reveals important additional findings. In Granelli's⁴ and Riede's⁵ studies, half of eligible babies with CCHD, presented with symptoms before screening could take place; 28/57 babies with CCHD in Granelli's and 18/36 in Riede's. In Granelli's,⁴ Over 10% of babies with CCHD (6/57) presented with acute collapse in hospital - the very situation that screening aims to prevent. It is well documented that babies with CCHD who collapse prior to surgery have worse outcomes and greater risk of neuro-developmental complications,¹ so these potentially avoidable collapses (i.e. if screening was earlier) may have significant consequences. Although earlier screening results in more test positive babies, it is important to balance a low FP rate with timely diagnosis. Some FP babies will be healthy- having transitional circulation - but others have life-threatening non-cardiac conditions and

the earlier these are identified, the better. In some countries, mothers and babies are discharged from hospital within 24 hours following birth and an increasing proportion is born at home. In these circumstances, later screening in hospital is not practical.

UK evidence - screening at a mean age of seven hours - reported a test positive rate of 0.8%⁷ (similar to PulseOx study⁶) With around 26 000 babies screened, nine CCHDs were identified and, within the FPs, 79% had a significant medical condition. One of the major concerns regarding a high FP rate is the increased need for specialist assessment - particularly echocardiography - which can be challenging in some areas. Only 29% of test-positive babies in the UK study underwent echocardiography (mainly because an alternative non-cardiac diagnosis was established) and the echo was positive in 48%.⁷ This compared favorably with babies in the same unit undergoing echocardiography for asymptomatic murmur⁷

The experience following the introduction of POS in New Jersey was recently reported.⁸ Almost 73 000 babies were screened (after 24 hours) and the FP rate was 0.04%. However only three babies with CCHD and only 12 babies with non-cardiac conditions were detected. Although the FP rate is admirably low, the number of babies with CCHD is also very low. In the UK it took 2873 screens to detect one CCHD vs. 24 231 screens in the US.⁷ The likelihood is, that in the US cohort, many babies with CCHD presented before screening took place. These important considerations led to the Nordic countries recommending screening at <24 hours⁹

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Differences in definition of a test positive result

The UK study used the PulseOx⁶ algorithm, which in addition to a difference in timing, has subtle differences in the definition of test positivity (figure 2). In the US algorithm, test positivity is defined as saturation <90% in either limb or saturations between 90-94% in *both* limbs, or a difference of >3% between the two, on 3 separate occasions (i.e. two retests each after 1 hour, before clinical assessment). In the UK, a test positive saturation must be 90-94% in *either* limb or a difference of >2% on two occasions (i.e. one retest after 2 hours which is *preceded* by clinical assessment).

Do these minor differences matter? Examining the raw pre/post saturation data from both studies and applying the US protocol to the PulseOx patients would have missed one CCHD (detected prenatally) and 2 serious CHDs. These numbers are small but may be important when scaled up nationally; further evidence is required before a precise estimate of the difference can be stated with conviction. The application of a second retest almost certainly reduces the FP rate (babies with transitional circulation improve between screens) but as the majority (up to 80%) of babies who test positive after one retest have a significant condition,⁷ the second retest before clinical assessment potentially introduces a delay in diagnosis and treatment, which may result in a worse outcome.

So, should the US screening algorithm remain as it is, or should a change be considered? Countries wishing to introduce screening may, quite rightly, wish to follow tried and tested practice but unfortunately there are limited data reporting outcomes of US screening. Further research is probably unnecessary,

1
2
3 however collection and analysis of saturation data from populations already
4
5 being screened is required to refine the minor differences in the algorithm.
6
7 The evidence to support a change in timing is perhaps more convincing, but is
8
9 important to accept that test positives will increase (to around 0.8%) with
10
11 earlier screening and many non-cardiac conditions are identified in addition.
12
13 POS uses hypoxemia as a proxy for CCHD and does not detect CCHD directly.
14
15 Given this, should we screen for all hypoxemic conditions rather than just CCHD?
16
17 The concern is that hypoxemia is not a condition as such and newborns may
18
19 have 'physiological' hypoxemia as the cardio-respiratory systems adapt to extra-
20
21 uterine life. Once again the earlier screening takes place the more likely this
22
23 'transitional circulation' is identified in test positive babies. The other major
24
25 concern is although we have good data for CCHD, there are no robust data on the
26
27 accuracy of POS for non-cardiac conditions. This presents difficulties for Public
28
29 Health decision-makers sanctioning POS as a valid test for these conditions.
30
31 Perhaps the best compromise is to continue POS for CCHD and accept that babies
32
33 detected with non-cardiac conditions (technically FPs, but could be considered
34
35 secondary targets) are an important additional benefit. Clinical staff and parents
36
37 should be made aware of this.
38
39
40
41
42
43
44
45

46 Until these issues are resolved and more data forthcoming, is it worth
47
48 considering an algorithm which has a consistent slightly higher FP rate but will
49
50 potentially identify more babies with life-threatening disease?
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Ewer AK. Review of pulse oximetry screening for critical congenital heart defects. *Current Opinions in Cardiology* 2013;28:92-6.
2. Kemper AR, Mahle WT, Martin GR, et al. Strategies for implementing screening for critical congenital heart disease. *Pediatrics* 2011;128:e1259–67.
3. Thangaratinam S, Brown K, Zamora J, et al. Pulse oximetry screening for critical congenital heart defects in asymptomatic newborn babies: a systematic review and meta-analysis. *Lancet* 2012;379:2459–64.
4. de Wahl Granelli A, Wennergren M, Sandberg K, et al. Impact of pulse oximetry screening on detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39 821 newborns. *BMJ* 2009;338:A3037.
5. Riede FT, Worner C, Dahnert I, et al. Effectiveness of neonatal pulse oximetry screening for detection of critical congenital heart disease in daily clinical routine—results from a prospective multicenter study. *Eur J Pediatrics* 2010;169:975–81.
6. Ewer AK, Middleton LJ, Furmston AT, et al. Pulse oximetry as a screening test for congenital heart defects in newborn infants (PulseOx): a test accuracy study. *Lancet* 2011;378:785–94.
7. Singh AS, Rasiah SV, Ewer AK. The impact of routine pre-discharge pulse oximetry screening in a regional neonatal unit. *Arch Dis Child Fetal and Neonatal* 2014; 99:F297-F302.
8. Garg LF, Van Naarden Braun K, Knapp MM, et al. Results from the New Jersey statewide critical congenital heart defects screening program. *Pediatrics* 2013;132: e314–23.
9. de-Wahl Granelli A*, Meberg A, Ojala T, Steensberh J, Oskarsson G, Mellander M. Nordic pulse oximetry screening – implementation status and proposal for uniform guidelines, *Acta Paediatr* 2014;103: 1136–1142.

Figure 1. USA algorithm




Figure 2 UK algorithm

